Literature DB >> 16239045

Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis.

Dimitrios N Samonakis1, Evangelos Cholongitas, Christos K Triantos, Paul Griffiths, Amar Paul Dhillon, Ulrich Thalheimer, David W Patch, Andrew K Burroughs.   

Abstract

Immunosuppression is a main determinant for the increased Hepatitis C Virus (HCV) replication after liver transplantation and the accelerated course of recurrent HCV liver disease. We present two patients both with diabetes, renal dysfunction with proteinuria converted to sirolimus therapy, who cleared serum HCV RNA without antiviral treatment. This is a potentially important observation that should stimulate study into factors that may help viral clearance from blood.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16239045     DOI: 10.1016/j.jhep.2005.08.005

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  11 in total

Review 1.  Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation.

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2014-05-27

Review 2.  Treatment of chronic hepatitis C in liver transplant candidates and recipients: Where do we stand?

Authors:  Chrysoula Pipili; Evangelos Cholongitas
Journal:  World J Hepatol       Date:  2015-06-28

3.  Temporal association between increased virus-specific Th17 response and spontaneous recovery from recurrent hepatitis C in a liver transplant recipient.

Authors:  Anil B Seetharam; Brian B Borg; Vijay Subramanian; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2011-12-27       Impact factor: 4.939

4.  The impact of sirolimus on hepatitis C recurrence after liver transplantation.

Authors:  Sonal Asthana; Christian Toso; Glenda Meeberg; David L Bigam; Andrew Mason; James Shapiro; Norman M Kneteman
Journal:  Can J Gastroenterol       Date:  2011-01       Impact factor: 3.522

5.  Rapamycin ameliorates the CTLA4-Ig-mediated defect in CD8(+) T cell immunity during gammaherpesvirus infection.

Authors:  D F Pinelli; B S Wakeman; M E Wagener; S H Speck; M L Ford
Journal:  Am J Transplant       Date:  2015-05-19       Impact factor: 8.086

6.  Antiviral treatment for hepatitis C virus infection after liver transplantation.

Authors:  Yasuhiko Sugawara; Sumihito Tamura; Norihiro Kokudo
Journal:  Hepat Res Treat       Date:  2010-11-01

7.  Spontaneous clearance of hepatitis C after liver and renal transplantation.

Authors:  C H Dale; P Burns; M McCutcheon; R Hernandez-Alejandro; P J Marotta
Journal:  Can J Gastroenterol       Date:  2009-04       Impact factor: 3.522

8.  Spontaneous clearance of HCV accompanying hepatitis after liver transplantation.

Authors:  Tomomi Kogiso; Etsuko Hashimoto; Yuichi Ikarashi; Kazuhisa Kodama; Makiko Taniai; Nobuyuki Torii; Hiroto Egawa; Masakazu Yamamoto; Katsutoshi Tokushige
Journal:  Clin J Gastroenterol       Date:  2015-09-05

9.  Everolimus, an mTORC1/2 inhibitor, in ART-suppressed individuals who received solid organ transplantation: A prospective study.

Authors:  Timothy J Henrich; Corinna Schreiner; Cheryl Cameron; Louise E Hogan; Brian Richardson; Rachel L Rutishauser; Amelia N Deitchman; Simon Chu; Rodney Rogers; Cassandra Thanh; Erica A Gibson; Arya Zarinsefat; Sonia Bakkour; Francesca Aweeka; Michael P Busch; Teri Liegler; Christopher Baker; Jeffrey Milush; Steven G Deeks; Peter G Stock
Journal:  Am J Transplant       Date:  2020-09-15       Impact factor: 9.369

10.  Determinant Factors of the Direct Medical Costs Associated with Genotype 1 Hepatitis C Infection in Treatment-Experienced Patients.

Authors:  Essè Ifèbi Hervé Akpo; Urbano Sbarigia; George Wan; Joris Kleintjens
Journal:  Drugs R D       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.